HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

LVMH

This article was originally published in The Rose Sheet

Executive Summary

Christian Dior Higher and Kenzo Flower fueled Perfumes & Cosmetics sales for the year, but division operating income dropped 19% to $130.4 mil. (€1=$.88) largely due to a slowdown in the economy, luxury goods retailer says in 1March 7 release. Selective Retailing division, which includes Sephora and Duty Free Sales, recorded operating loss of $169.8 mil. from loss of $1.8 mil. in 2000. Loss in Selective Retailing contributed to lower consolidated earnings, LVMH says. Group generated net income of $8.8 mil. in 2001 compared to $639.9 mil. the prior year, remaining in the black due to a $756.2 mil. gain related to the sale of its Gucci shares...

You may also be interested in...



Sephora Aiming For Profitability By 2003 – LVMH

LVMH is working to achieve a "pronounced improvement" in profitability in its Selective Distribution division this year, Financial Communications Director Christopher Hollis said during the luxury goods manufacturer's first quarter sales presentation April 24

Scrip M&A Podcast: Which Companies Could Be Acquired Next?

The editorial team from Scrip discusses the M&A potential of various emerging biopharmas, such as Viking, Verona, Altimmune, Xenon and Crinetics.

New EU Filings

Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS010106

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel